The Pacific Cancer Research Consortium (PCRC) brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. The PCRC includes Swedish Cancer Institute in Seattle and its former U10 affiliates (the Puget Sound Oncology Consortium), Providence Portland Medical Center in Portland and its former Community Clinical Oncology Program affiliates (the Western Oncology Research Consortium), and Mountain States Tumor Institute in Boise. Under a multiple PI/PD structure, the 3 primary components of the PCRC will define and facilitate the clinical trial and cancer care delivery research agenda across 24 participating components and 14 sub-components in Washington, Oregon, Idaho, Alaska, and California. Each of our primary component sites has decades of experience conducting clinical trials in cancer and plan to participate in all aspect of study design and conduct NCI-approved clinical studies and cancer care delivery research, with particular focus on facilitating the participation of minorities and underserved populations across all study types and settings within our catchment areas, providing bio specimen banking and sharing practices within the participating institutions and with our research bases, and incorporating genomic medicine and targeted therapies into our portfolio of research capabilities. We also plan to build a multicenter infrastructure and research agenda for cancer care delivery research to support the trials proposed by the NCTN, allowing us to participate in the development of novel approaches to CC DR studies.

Public Health Relevance

This joint application and the proposed structure com e from our desire to create the strongest NCORP application from our region that will excel in patient accrual, and foster new and close collaboration between investigators. We believe that our structure will accelerate the translation of knowledge gained from cancer clinical trials into clinical practice and enhance the science, the treatments, and the delivery of care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Pearson, Deborah
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Swedish Medical Center, First Hill
United States
Zip Code
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Smith 2nd, John W; Buyse, Marc E; Rastogi, Priya et al. (2017) Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial o Clin Breast Cancer 17:48-54.e3
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Janelsins, Michelle C; Heckler, Charles E; Peppone, Luke J et al. (2017) Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol 35:506-514
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2017) A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol :
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16

Showing the most recent 10 out of 23 publications